The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate

Summary

The aim of this study was to investigate the mechanism by which the anticoagulant activity of dermatan sulfate (DS) is increased by low molecular weight heparin (LMWH). In platelet poor plasma, LMWH enhances the effect of DS on thrombin (IIa) inhibition as determined by thrombin clotting times and with a chromogenic substrate assay. Analysis of the results of the chromogenic assays using either the algebraic fractional or the graphic isobole method suggests that LMWH has an additive effect on the anti-IIa activity of DS. This additive effect was lost when the experiments were repeated in plasma immunodepleted of antithrombin III (ATIII), indicating that the anti-IIa activity of LMWH is ATIII-dependent. To further explore the mechanism of the interaction between LMWH and DS, ¹²⁵I-labeled IIa was added to plasma in the presence or absence of DS and/or LMWH and the formation of IIa-inhibitor complexes was assessed using SDS-PAGE followed by autoradiography. DS addition selectively increases the formation of heparin cofactor II (HCII)-IIa complexes, whereas LMWH enhances ATIII-IIa complex generation. Compared to plasma containing DS alone, the formation of ATIII-IIa complexes also is increased when the combination of DS and LMWH is added. These findings suggest that the additive effect of LMWH on the anti-IIa activity of DS reflects their different modes of IIa inhibition; DS potentiates IIa inhibition by HCII, while LMWH catalyses ATIII-dependent IIa inactivation. The potential clinical significance of these findings requires further investigation.

• References

• 1 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 2 Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6916
• 3 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 4 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effect of heparin. Blood 1985; 65: 198-201
• 5 Thomas DP, Merton RE, Barrowcliffe TW. The relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs. Ann NY Acad Sci 1989; 556: 313-320
• 6 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986; 64: 309-317
• 7 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 1989; 556: 304-312
• 8 Agnelli G, Cosmi B, DiFilippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli R, Nenci GG. A randomized, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 1992; 67: 203-208
• 9 Scully MF, Melissari E, Ellis V, Kakkar VV. Increased anti factor Xa/aPTT ratio of LMW heparin by inclusion of dermatan sulfate. Thromb Haemostas 1989; 62: 511 (abstract)
• 10 Cadroy Y, Dol F, Caranobe C, Petitou M, Lormeau JC, Sie P, Choay J, Boneu B. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not. Thromb Haemostas 1988; 59: 295-298
• 11 Thomas DP, Gray E, Merton RE. Potentiation of the antithrombotic action of dermatan sulfate by small amounts of heparin. Thromb Haemostas 1990; 64 (02) 290-293
• 12 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
• 13 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 14 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by simple radial immunodiffusion. Immunochemistry 1965; 2: 235-238
• 15 Denson KWE. The sensitivity of human and bovine thrombin to heparin in plasma. Thromb Res 1981; 23: 207-213
• 16 Marchalonis JJ. An enzyme method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 229
• 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond) 1970; 227: 680-685
• 18 Swanstrom R, Shank PR. X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes ³²P and ¹²⁵ I. Anal Biochem 1978; 86z: 184-192
• 19 Berenbaum MC. Synergy, additivism and antagonism in immunosup-pression. A critical review. Clin Exp Immunol 1977; 29: 1-18
• 20 Berenbaum MC. What is synergy?. Pharmacol Rev 1989; 41: 93-141
• 21 Conard J, Brosstad F, Lie LarsenM, Samama M, Abildgaard U. Molar antithrombin III concentrations in normal human plasma. Haemostasis 1983; 13: 363-368
• 22 Bjork I, Olson ST, Shore JD. Molecular mechanism of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Heparin. Chemical, Biological Properties and Clinical Applications. Lane DA, Lindhai U. (eds) Edward Arnold; 1989. pp 230-255
• 23 Tollefsen DM, Sugimori T, Maimone MM. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II. Semin Thromb Haemostas 1990; 16S: 66-70